Currently Viewing:
COA 2017-ONCOLOGY PAYMENT REFORM
Currently Reading
Dr Roger Brito Discusses Practitioners Taking on 2-Sided Risk
February 12, 2018
Dr Peter Aran Discusses Year 1 Feedback on OCM
February 05, 2018
Dr Roger Brito on When Providers Should Be Involved in Reimbursement Model Development
January 31, 2018
Dr Mark Fendrick: How Expensive Therapies Fit Into VBID for Oncology
January 29, 2018
Bo Gamble Explains How COA Helps Practices Prepare for OCM
January 27, 2018
Dr Peter Aran on What Oncologists Implementing OCM Can Learn From Existing Models
January 24, 2018
Dr Roger Brito Discusses Implementing Alternative Payment Models and Its Challenges
January 20, 2018
Terrill Jordan Discusses the Process of Customizing an EMR to Adapt to OCM
January 19, 2018
Dr Mark Fendrick: Setting Cost-Sharing Based on Value, Not Price, in Cancer Care
January 18, 2018
David Merrill and John Robinson Discuss Barriers to APMs, Factors of Interest
January 15, 2018
Dr Jeff Patton Discusses Preparing for OCM, Seeing Improved Outcomes and Savings
January 12, 2018
Dr Peter Aran on Involving Providers in Development Process of New Reimbursement Models
January 11, 2018
Sarah Cevallos on Her Advice for Practices Looking to Participate in OCM
January 10, 2018
Dr Roger Brito: What Patients Should Know About Alternative Payment Models, OCM
January 09, 2018
Dr Mark Fendrick on Indication-Based Drug Pricing in Cancer Care
January 07, 2018
Bo Gamble on COA's Role in 2018
January 05, 2018
Judy Berger on What Southwest Airlines Is Doing in Oncology
January 04, 2018
Terrill Jordan Discusses Making Refinements in Year 2 of OCM
January 03, 2018
Sarah Cevallos: Physicians Need More Data to Determine if 2-Sided Risk is Appropriate
December 26, 2017

Dr Ira Klein on Pharmaceutical Interest in Alternative Payment Models

Pharmaceutical companies would like to see value-based contracts that are multi-year and over large populations, said Ira Klein, MD, MBA, FACP, senior director of healthcare quality strategy for the Strategic Customer Group at Janssen Pharmaceuticals.


Pharmaceutical companies would like to see value-based contracts that are multi-year and over large populations, said Ira Klein, MD, MBA, FACP, senior director of healthcare quality strategy for the Strategic Customer Group at Janssen Pharmaceuticals.

Transcript (slightly moified)

What are pharmaceutical companies interested in with respect to alternative payment models?

I think that anything that really helps in unlocking the true value of a product over time is what the pharmaceutical industry is interested in. Now, if you think about the research and development time cycle, and the amount of failure of potential drugs to make it to market, it’s really a very long ramp up for the few products that actually make it. So, when you think about measuring a value in value-based contracts, it’s probably difficult to actually capture the real value in a 12-month contract, because drugs by meliorating disease, meliorating suffering, tend to have their real value explained over a number of years. Actuarially, while this may become more difficult, I think value-based contracts, if they can be multi-year and over large populations, those are the things we would like to see in the contract.

We’d also like to be able to measure some of the factors that are not traditionally measured, but are very important to patients, such as their quality of life, their outcomes, and what it means for them to be able to care for others, maintain employment, and participate in meaningful activities that they otherwise wouldn’t be able to participate in.

Additionally, I just want to say that as we move into a more aggregated system, where the delivery side has become more group-oriented in ACOs and IDNs, we think that the ability to manage these value-based contracts will become easier because these aggregated delivery systems will be able to present us with that large set of holistic data that I referred to that we will need to actually show the real value of the products in the marketplace for real patients.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!